Literature DB >> 17385786

Evaluating adverse events after vaccination in the Medicare population.

Dale R Burwen1, Lawrence La Voie, M Miles Braun, Peter Houck, Robert Ball.   

Abstract

PURPOSE: Post-licensure observational studies using large linked databases can provide important data about whether adverse events are associated with vaccines, but databases that have been used may not have sufficient statistical power to examine rare events, and may underrepresent the elderly. We assessed the utility of Medicare data for evaluating adverse events after influenza and pneumococcal vaccines, by using an example involving selected clinical conditions, and evaluating aspects of data quality relevant to vaccine safety analyses.
METHODS: We used 2001 data from the National Claims History File and Enrollment Database to determine if hospitalization for urinary tract infection (not likely associated with vaccination) or for cellulitis and abscess of the upper arm and forearm is associated with vaccination.
RESULTS: For influenza vaccine, the 7-day period after vaccination did not demonstrate an elevation in hospitalization with cellulitis and abscess of the upper arm and forearm; for pneumococcal vaccine, a clear peak was evident. No increase in urinary tract infection was found after either influenza or pneumococcal vaccine. Having a prior Medicare claim for pneumococcal vaccine within 5 years was a risk factor for hospitalization with cellulitis and abscess of the upper arm and forearm (relative risk, 2.6; 95% confidence limits (CL), 1.3, 5.0).
CONCLUSIONS: Medicare data are a useful source for evaluating adverse events after vaccination. Screening analyses can be performed using administrative data, but medical record review to validate diagnoses will often be needed for rigorous study of vaccine-adverse event associations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17385786     DOI: 10.1002/pds.1390

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study.

Authors:  Xiaoyan Wang; George Hripcsak; Marianthi Markatou; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2009-03-04       Impact factor: 4.497

2.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Authors:  Sharon K Greene; Martin Kulldorff; Edwin M Lewis; Rong Li; Ruihua Yin; Eric S Weintraub; Bruce H Fireman; Tracy A Lieu; James D Nordin; Jason M Glanz; Roger Baxter; Steven J Jacobsen; Karen R Broder; Grace M Lee
Journal:  Am J Epidemiol       Date:  2009-12-04       Impact factor: 4.897

3.  Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010.

Authors:  Dale R Burwen; Sukhminder K Sandhu; Thomas E MaCurdy; Jeffrey A Kelman; Jonathan M Gibbs; Bruno Garcia; Marianthi Markatou; Richard A Forshee; Hector S Izurieta; Robert Ball
Journal:  Am J Public Health       Date:  2012-02-16       Impact factor: 9.308

4.  Signal Detection of Adverse Events Following Pneumococcal Vaccines from the Korea Adverse Event Reporting System Database, 2005-2016.

Authors:  Kwan Soo Kim; In Sun Oh; Hyun Jeong Kim; Inmyung Song; Min Soo Park; Ju Young Shin
Journal:  Yonsei Med J       Date:  2020-03       Impact factor: 2.759

Review 5.  Sepsis, parenteral vaccination and skin disinfection.

Authors:  Ian F Cook
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.